Sugammadex Sodium (0343306-71-8)

Systematic Name: 6A,6B,6C,6D,6E,6F,6G,6H-Octakis-S-(2-carboxyethyl)-6A,6B,6C,6D,6E,6F,6G,6H-octathio-γ-cyclodextrin sodium salt (1:8)
Trade Name(s): Bridion

Molecular Formula: C₇₂H₁₀₄Na₈O₄₈S₈

Molecular Weight: 2178.01 g/mol

Physical Properties: Clear, colorless to slightly yellow-brown aqueous solution

Therapeutic Category: Central nervous system agent – nondepolarizing muscle relaxant antagonist

Sugammadex Sodium belongs to a class of drugs called selective relaxant binding agents (SRBAs), used to cancel the effects of neuromuscular blocking agents (NMBAs). NMBAs are used during surgery and other medical procedures for anesthetic purposes (specifically, to provide skeletal muscle relaxation).  Sugammadex is used to reverse the effects of the NMBAs rocuronium and vecuronium bromide in adults. In the EU, it is also approved for use in children from age 2 to reverse the effects of rocuronium.

Administered as an intravenous infusion, sugammadex can provide rapid reversal when needed, and can be used to reverse both shallow and profound neuromuscular block. In addition, it obviates the need for co-administration with antimuscarinic agents since it does not inhibit the enzyme acetylcholinesterase.

Sugammadex was approved by the EU in 2008 and by the FDA in 2015, under the trade name Bridion. It is a cyclic organic molecule (a gamma cyclodextrin) that is modified to extend cavity size, allowing facile encapsulation of rocuronium or vecuronium.